The endocrine prevention of breast cancer

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 4, 2008, Pages 615-623

  Howell, Anthony ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

aromatase inhibitors; high risk women; prevention; raloxifene; tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; EXEMESTANE; LETROZOLE; PLACEBO; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; ENDOMETRIUM CANCER; FOLLOW UP; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; LOW DRUG DOSE; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; RISK REDUCTION; THROMBOEMBOLISM; VASOMOTOR DISORDER;

AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 54349093330     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.09.002     Document Type: Review

References (32)

1. Howell A., Clarke R.B., Evans G., et al. Estrogen deprivation for breast cancer prevention. Recent Results in Cancer Research 174 (2007) 151-167
2. Feinleib M. Breast cancer and artificial menopause: a cohort study. Journal of the National Cancer Institute 41 (1968) 315-329
3. Hirayama T., and Wynder E.L. A study of the epidemiology of cancer of the breast II. The influence of hysterectomy. Cancer 5 (1962) 28-38
4. Trichopoulos D., MacMahon B., and Cole P. Menopause and breast cancer risk. Journal of the National Cancer Institute 48 (1972) 605-613
5. Narod S.A., Brunet J.S., Ghadirian P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356 (2000) 1876-1881
6. Gronwald J., Tung N., Foulkes W.D., et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. International Journal of Cancer 118 (2006) 2281-2284
7. Rebbeck T.R., Lynch H.T., and Neuhausen S.L. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. The New England Journal of Medicine 346 (2002) 1616-1622
8. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk reducing salpino-oophorectomy in women with a BRCA1 and BRCA2 mutation. The New England Journal of Medicine 346 (2002) 1609-1615
9. Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology 22 (2004) 2328-2335
10. Olson J.E., Sellers T.A., Iturria S.J., et al. Bilateral oophorectomy and breast cancer risk reduction among women with a family history. Cancer Detection and Prevention 28 (2004) 357-360
11. Eisen A., Lubinski J., Klijn J., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case control study. Journal of Clinical Oncology 23 (2005) 7491-7496
12. Cuzick J., and Baum M. Tamoxifen and contralateral breast cancer. Lancet 2 (1985) 282
13. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
14. Cuzick J. Aromatase inhibitors for breast cancer prevention. Journal of Clinical Oncology 23 (2005) 1636-1643
15. Powles T.J., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352 (1998) 98-101
16. Powles T.J., Ashley S., Tidy V.A., et al. 20 year follow up of the Royal Marsden tamoxifen breast cancer prevention trial. Journal of the National Cancer Institute 99 4 (2007) 283-290
17. Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (2002) 817-824
18. Cuzick J., Forbes J., Sestak I., et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96 month follow up of the IBIS-I study. Journal of the National Cancer Institute 99 4 (2007) 272-282
19. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 90 (1998) 1371-1388
20. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 97 (2005) 1652-1662
21. Cummings S.R., Eckert S., and Krueger K.A. The effect of Raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomised trial. JAMA : The Journal of the American Medical Association 281 (1999) 2189-2197
22. Martino S., Cauley J.A., Barrett-Connor E., et al. Continuing outcomes relevant to evista: breast cancer incidence in postmenopausal osteoporotic women in a randomised trial of raloxifene. Journal of the National Cancer Institute 96 (2004) 1751-1761
23. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. The New England Journal of Medicine 355 (2006) 125-137
24. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA : The Journal of the American Medical Association 295 (2006) 2727-2741
25. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 361 (2003) 296-300
26. Pike M.C., and Spicer D.V. The chemoprevention of breast cancer by reducing sex steroid exposure: perspectives from epidemiology. Journal of Cellular Biochemistry. Supplement 17G (1993) 26-36
27. Clarke R.B., Howell A., Potten C., et al. Dissociation between steroid receptor expression and cell proliferation suggests cellular hierarchies in the human breast. Cancer Research 57 (1997) 4987-4992
28. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women's health initiative randomized trial. JAMA : The Journal of the American Medical Association 289 24 (2003) 3243-3253
29. Armstrong K., Schwartz J.S., Randall T., et al. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. Journal of Clinical Oncology 22 (2004) 1045-1054
30. Veronesi U., Maisonneuvre P., Rotmensz N., et al. Tamoxifen for the prevention of breast cancer: late results of the Italian randomised tamoxifen prevention trial among women with hysterectomy. Journal of the National Cancer Institute 99 (1997) 727-737
31. Veronesi U., Maisonneuve P., Rotmensz N., et al. Italian randomised trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high risk women. Journal of the National Cancer Institute 95 (2003) 160-165
32. Decensi A., Galli A., and Veronesi U. HRT opposed to low-dose tamoxifen (HOT study): rationale and design. Recent Results in Cancer Research 163 (2003) 104-111